BridgeBio Pharma (NASDAQ:BBIO) Director Hannah Valantine Sells 2,808 Shares of Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Hannah Valantine sold 2,808 shares of the business’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $68.00, for a total transaction of $190,944.00. Following the completion of the transaction, the director directly owned 11,455 shares of the company’s stock, valued at approximately $778,940. This represents a 19.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hannah Valantine also recently made the following trade(s):

• On Tuesday, June 23rd, Hannah Valantine sold 2,196 shares of BridgeBio Pharma stock. The stock was sold at an average price of $68.57, for a total value of $150,579.72.

BridgeBio Pharma Stock Up 0.9%

Shares of BBIO opened at $69.26 on Thursday. BridgeBio Pharma, Inc. has a 12-month low of $41.80 and a 12-month high of $84.94. The firm has a market capitalization of $13.56 billion, a PE ratio of -18.52 and a beta of 0.97. The stock’s fifty day simple moving average is $69.20 and its 200-day simple moving average is $71.86.

BridgeBio Pharma (NASDAQ:BBIO) last issued its earnings results on Thursday, May 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The firm had revenue of $194.51 million for the quarter, compared to the consensus estimate of $178.07 million. During the same quarter in the previous year, the business earned ($0.88) earnings per share. The company’s revenue was up 66.8% on a year-over-year basis. Analysts anticipate that BridgeBio Pharma, Inc. will post -2.29 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on BBIO shares. Barclays reiterated an “overweight” rating on shares of BridgeBio Pharma in a report on Tuesday, March 10th. Morgan Stanley increased their price target on BridgeBio Pharma from $94.00 to $98.00 and gave the company an “overweight” rating in a research report on Thursday, May 28th. Oppenheimer cut their price target on shares of BridgeBio Pharma from $83.00 to $81.00 and set an “outperform” rating for the company in a research note on Wednesday, February 25th. Citigroup started coverage on BridgeBio Pharma in a research report on Tuesday, May 19th. They issued a “neutral” rating and a $82.00 price objective for the company. Finally, Truist Financial lifted their target price on shares of BridgeBio Pharma from $95.00 to $102.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Twenty-one investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, BridgeBio Pharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $92.90.

Institutional Investors Weigh In On BridgeBio Pharma

Large investors have recently added to or reduced their stakes in the stock. Parallel Advisors LLC raised its holdings in BridgeBio Pharma by 552.6% in the 1st quarter. Parallel Advisors LLC now owns 894 shares of the company’s stock valued at $66,000 after acquiring an additional 757 shares in the last quarter. Avidity Partners Management LP acquired a new stake in shares of BridgeBio Pharma during the 1st quarter worth $711,000. Janus Henderson Group PLC increased its position in shares of BridgeBio Pharma by 19.8% in the first quarter. Janus Henderson Group PLC now owns 13,179,013 shares of the company’s stock worth $978,608,000 after purchasing an additional 2,178,556 shares during the period. California State Teachers Retirement System increased its position in shares of BridgeBio Pharma by 23.7% in the first quarter. California State Teachers Retirement System now owns 165,703 shares of the company’s stock worth $12,305,000 after purchasing an additional 31,797 shares during the period. Finally, Rock Springs Capital Management LP raised its stake in BridgeBio Pharma by 23.9% in the first quarter. Rock Springs Capital Management LP now owns 128,250 shares of the company’s stock valued at $9,524,000 after purchasing an additional 24,750 shares in the last quarter. Institutional investors and hedge funds own 99.85% of the company’s stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.